The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET

Breast Cancer Research

Volumn 12, Issue 3, 2010, Pages

  Schneider Kolsky, Michal E ^a   Hart, Stewart ^b   Fox, Jane ^b   Midolo, Peter ^b   Stuckey, John ^b   Hofman, Michael ^b   Ganju, Vinod ^b  

^a MONASH UNIVERSITY   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; RADIOPHARMACEUTICAL AGENT; TAXOID;

ADULT; AGED; ARTICLE; BREAST CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL; TUMOR VOLUME; ULTRASOUND; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; LUNG CARCINOMA; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 78149475497     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2591     Document Type: Article

References (31)

1. Warburg O, Wind F, Neglers E. On the metabolism of tumors in the body. Metabolism of Tumors 1930, 264-270. London: Constable, Warburg O.
2. McDermott GM, Welch A, Staff RT, Gilbert FJ, Schweiger L, Semple SIK, Smith TAD, Hutcheon AW, Miller ID, Smith IC, Heys SD. Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat 2007, 102:75-84. 10.1007/s10549-006-9316-7, 16897427.
3. Krak NC, Hoekstra OS, Lammertsma AA. Measuring response to chemotherapy in locally advanced breast cancer: methodological considerations. Eur J Nucl Med Mol Imaging 2004, 31(Suppl 1):S103-S111. 10.1007/s00259-004-1532-y, 15103507.
4. Beriollo-Riedinger A, Touzery C, Riedinger J, Toubeau M, Coudert B, Arnould L, Biochet C, Cochet A, Fumoleau P, Brunotte F. [18F] FDG-PET predicts complete pathological respionse of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 2007, 34:1915-1924. 10.1007/s00259-007-0459-5, 17579854.
5. Emmering J, Krak NC, Van der Hoeven JJ, Spreeuwenberg MD, Twisk JW, Meijer S, Pinedo HM, Hoekstra OS. Preoperative [18F] FDG-PET after chemotherapy in locally advanced breast cancer: prognostic value as compared with histopathology. Ann Oncol 2008, 19:1573-1577. 10.1093/annonc/mdn185, 18552360.
6. Li D, Yao Q, Li L, Wang L, Chen J. Correlation between hybrid 18F-FDG PET/CT and apoptosis induced by neoadjuvant chemotherapy in breast cancer. Cancer Biol Ther 2007, 6:1442-1448. 10.4161/cbt.6.9.4621, 17827982.
7. Kuerer HM, Newman LA, Buzdar AU, Hunt KK, Dhingra K, Buchholz TA, Binkley SM, Ames FC, Feig BW, Ross MI, Hortobagyi GN, Singletary SE. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg 1998, 176:502-509. 10.1016/S0002-9610(98)00253-0, 9926779.
8. Machiavelli MR, Romero AO, Perez JE, Lacava JA, Domínguez ME, Rodríguez R, Barbieri MR, Romero Acuña LA, Romero Acuña JM, Langhi MJ, Amato S, Ortiz EH, Vallejo CT, Leone BA. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 1998, 4:125-131.
9. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neodajuvant chemotherapy. J Clin Oncol 1999, 17:460-469.
10. Honkop AH, van Diest PJ, de Jong JS, Linn SC, Giaccone G, Hoekman K, Wagstaff J, Pinedo HM. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 1998, 77:621-626. 2149927, 9484820.
11. Heller W, Mazhar D, Ward R, Sinnett HD, Lowdell C, Phillips R, Shousha S, Fayaz A, Palmeri C, Coombes RC. Neodajuvant 5-flourouracil, epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer. Oncol Rep 2007, 17:253-259.
12. Oshida M, Uno K, Suzuki M, Nagashima T, Hashimoto H, Yagata H, Shishikura T, Imazeki K, Nakajima N. Predicting the prognosis of breast carcinoma patients with positron emission tomography using 2-deoxy-2-[18F]flouro-D-glucose. Cancer 1998, 82:2227-2234. 10.1002/(SICI)1097-0142(19980601)82:11<2227::AID-CNCR18>3.0.CO;2-W, 9610703.
13. Inoue T, Yutani K, Taguchi T, Tamaki Y, Shiba E, Noguchi S. Preoperative evaluation of prognosis in breast cancer patients by [(18)F2-deoxy-2-flouro-D-glucose-positron emission tomography. J Cancer Res Clin Oncol 2004, 130:273-278. 10.1007/s00432-003-0536-5, 14986112.
14. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Charlop A, Lawton TJ, Schubert EK, Tseng J, Livingston RB. Blood flow and metabolism in locally advanced breast cancer (LABC): relationship to response to therapy. J Nucl Med 2002, 43:500-509.
15. Schelling M, Avril N, Naehrig J, Kuhn W, Römer W, Sattler D, Werner M, Dose J, Jänicke F, Graeff H, Schwaiger M. Positron emission tomography using F-18 flourodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000, 18:1689-1695.
16. Kim SJ, Kim SK, Lee ES, Ro J, Kang S. Predictive value of [18]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol 2004, 15:1352-1357. 10.1093/annonc/mdh345, 15319241.
17. Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 2005, 35:84-99. 10.1053/j.semnuclmed.2004.11.001, 15765372.
18. Riccabona Nelson TR, Pretorius DH. Three-dimensional ultrasound: accuracy of distance and volume measurements. Ultrasound Obstet Gynecol 1996, 7:429-434. 10.1046/j.1469-0705.1996.07060429.x, 8807760.
19. Di Vici P, Rossi VS, Botti C, Vitucci C, Ferranti FR, Saracca E, Di Lauro L, Corsetti S, Foggi P, Fattoruso SIS, Lopez M. Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment. Clin Ter 2008, 159:453-456.
20. Alavi A, Lakhani P, Mavi A, Kung JW, Zhuang H. PET: a revolution in medical imaging. Radiol Clin North Am 2004, 42:983-1001. 10.1016/j.rcl.2004.08.012, 15488553.
21. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormotherapy using positron emission tomography: Initial evaluation. J Clin Oncol 1993, 11:2101-2111.
22. Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L, Ricaud M, Bourbuloux E, Doutriaux I, Clouet M, Berton-Rigaud D, Bouriel C, Delecroix V, Garin E, Rouquette S, Resche I, Kerbrat P. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F] flourodeoxyglucose positron emission tomography. J Clin Oncol 2006, 24:5366-5372. 10.1200/JCO.2006.05.7406, 17088570.
23. Kumar A, Kumar R, Seenu V, Gupta SD, Chawla M, Malhotra A, Mehta SN. The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Eur Radiol 2009, 19:1347-1357. 10.1007/s00330-009-1303-z, 19214522.
24. Duch J, Fuster D, Munoz M, Fernandez P, Paredes P, Fontanillas M, Guzman F, Rubi S, Lomena F, Pons F. 18F-FDG-PET/CT ofr early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging 2009, 36:1551-1557. 10.1007/s00259-009-1116-y, 19326117.
25. Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F, Waikar S, Whitaker T, Ah-See AK, Eremin O, Heys SD, Gilbert FJ, Sharp PF. Positron emission tomography using [(18)F]-flourodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000, 18:1676-1688.
26. Jung SY, Kim S, Nam B, Min S, Lee S, Park C, Kwon Y, Kim E, Ko K, Park I, Lee K, Shin K, Lee S, Kim S, Kang H, Ro J. Prognostic impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy. Ann Surg Oncol 2009, 17:247-253. 10.1245/s10434-009-0710-3, 19777177.
27. Herbst RS, Khuri FR. Mode of action of docetaxel - a basis for combination with novel anticancer agents. Cancer Treat Rev 2003, 29:407-415. 10.1016/S0305-7372(03)00097-5, 12972359.
28. Noguchi A. Predictive factors for response to docetaxel in human breast cancers. Cancer Sci 2006, 97:813-820. 10.1111/j.1349-7006.2006.00265.x, 16805818.
29. Baer HD, Anderson S, Smith RE, Geyer CE, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL, Wolmark N. Sequential preoperative or postoperative dicetaxel added to preoperative doxoribicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 2006, 24:2019-2026. 10.1200/JCO.2005.04.1665, 16606972.
30. Mamounas EP. Can we approach zero relapse in breast cancer?. Oncologist 2005, 10:9-17. 10.1634/theoncologist.10-90002-9, 16272454.
31. Ganju V, Strickland A, Hart S, Fox J, Stuckey J, Baldey A, Schneider-Kolsky ME, Susil B, Wu D, Rogers P. Identification of predictive markers for tumour response to neoadjuvant chemotherapy (NCT) treatment for locally advanced breast cancer. Eur J Cancer 2007, 5 Suppl:104.